Item 1. Security and Issuer.
This Amendment No. 2 (the “Amendment No. 2”) to Schedule 13D supplements and amends the statement on Schedule 13D of Clarus Lifesciences II, L.P., Clarus Ventures II GP, L.P., Clarus Ventures II, LLC, Robert Liptak, Nicholas Simon, Nicholas Galakatos, Dennis Henner, Kurt Wheeler, Michael Steinmetz and Finny Kuruvilla originally filed on July 11, 2013 (the “Schedule 13D”) and Amendment No. 1 thereto filed on February 13, 2014 relating to the shares of common stock, $0.0001 par value per share (the “Shares”), of NanoString Technologies, Inc., a Delaware corporation (the “Issuer”), having its principal executive offices located at 530 Fairview Avenue N, Suite 2000, Seattle, WA 98109.
Certain terms used but not defined in this Amendment No. 2 have the meanings assigned thereto in the Schedule 13D (including Amendment No. 1 thereto). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D (including Amendment No. 1 thereto).
Item 5. Interest in Securities of the Issuer.
(a) Clarus II is the record owner of 3,959,440 Shares and 162,408 warrants to purchase Shares (collectively, the “Clarus II Shares”), which would represent approximately 21.13% of the Issuer’s total issued and outstanding Common Stock. Such percentage is calculated based on 19,506,957 shares of Common Stock outstanding as of October 30, 2015, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 3, 2015. As the sole general partner of Clarus II GPLP, Clarus II GPLLC may be deemed to own beneficially the Clarus II Shares. As individual managing directors of Clarus II GPLLC, each of the Managers may be deemed to own beneficially the Clarus II Shares. Each Reporting Person disclaims beneficial ownership of all shares of Common Stock other than those shares which such person owns of record.
As of December 31, 2015, Galakatos is the record owner of options to purchase 21,922 shares of Common Stock (the “Galakatos Options”). Accordingly, Galakatos may be deemed to own beneficially the Galakatos Options and Clarus II Shares. As of December 31, 2015, Kuruvilla is the record owner of options to purchase 14,615 shares of Common Stock (the “Kuruvilla Options”). Accordingly, Kuruvilla may be deemed to own beneficially the Kuruvilla Options and Clarus II Shares.
| (b) | Regarding the number of shares as to which such person has: |
| (i) | sole power to vote or to direct the vote: See line 7 of cover sheets |
| (ii) | shared power to vote or to direct the vote: See line 8 of cover sheets |
| (iii) | sole power to dispose or to direct the disposition: See line 9 of cover sheets. |
| (iv) | shared power to dispose or to direct the disposition: See line 10 of cover sheets |
| (c) | Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days. |
| (d) | No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, securities beneficially owned by any of the Reporting Persons. |
Item 7. Material to be Filed as Exhibits.
Exhibit 99.1 – Agreement regarding filing of joint Schedule 13D.
Exhibit 99.2 – Power of Attorney regarding filings under the Act.